Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma

Leukemia

Volumn 28, Issue 4, 2014, Pages 951-954

  Silbermann, R ^a   Bolzoni, M ^b   Storti, P ^b   Guasco, D ^b   Bonomini, S ^b   Zhou, D ^a   Wu, J ^a   Anderson, J L ^a   Windle, J J ^c   Aversa, F ^b   David Roodman, G ^a,d   Giuliani, N ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PARMA   (Italy)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; INTERLEUKIN 3; MACROPHAGE DERIVED CHEMOKINE; MONOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

BONE DESTRUCTION; BONE MARROW; BONE REMODELING; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; LETTER; MORPHOMETRICS; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; UPREGULATION;

ACTIVINS; ANIMALS; BONE DISEASES; HUMANS; INTERLEUKIN-3; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND;

EID: 84898456500     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.385     Document Type: Letter

References (14)

1. Roodman GD. Mechanisms of bone metastasis. New Engl J Med 2004; 350: 1655-1664.
2. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992-3996. (Pubitemid 44913267)
3. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103: 2308-2315. (Pubitemid 38326251)
4. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106: 1407-1414. (Pubitemid 41129608)
5. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D et al. Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 2013; 27: 1697-1706.
6. Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D. Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol Cellular Endocrinol 2009; 310: 11-20.
7. Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 2012; 23: 2681-2686.
8. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124-5129.
9. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J et al. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 2008; 105: 7082-7087. (Pubitemid 351754533)
10. Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE, Ucran J et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 2010; 46: 1082-1088.
11. Scullen T, Santo L, Vallet S, Fulciniti M, Eda H, Cirstea D et al. Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia 2013; 27: 1715-1721.
12. Fuller K, Bayley KE, Chambers TJ. Activin A is an essential cofactor for osteoclast induction. Biochem Bioph Res Co 2000; 268: 2-7. (Pubitemid 30116600)
13. Gaddy-Kurten D, Coker JK, Abe E, Jilka RL, Manolagas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 2002; 143: 74-83. (Pubitemid 34056405)
14. Sakai R, Eto Y, Ohtsuka M, Hirafuji M, Shinoda H. Activin enhances osteoclast-like cell formation in vitro. Biochem Bioph Res Co 1993; 195: 39-46. (Pubitemid 23266493)